Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXAS1 | P24557 | 1/20 | 0.48 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.47 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.42 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.42 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.42 |
| ▸ | GPR35 | Q9HC97 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | DHODH | Q02127 | 2/20 | 0.38 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.38 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.38 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.38 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.38 |
| ▸ | CDC25B | P30305 | 2/20 | 0.37 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.37 |
| ▸ | CTSB | P07858 | 1/20 | 0.37 |
| ▸ | MMP9 | P14780 | 1/20 | 0.37 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.37 |
| ▸ | DNMT3B | Q9UBC3 | 1/20 | 0.37 |
| ▸ | DNMT3L | Q9UJW3 | 1/20 | 0.37 |
| ▸ | DNMT3A | Q9Y6K1 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3589587 | 0.86 | TBXAS1 (0.47) | TBXAS1PTPN1NR4A1NR4A2NR4A3 | |
| SCHEMBL3583506 | 0.86 | TBXAS1 (0.47) | TBXAS1PTPN1NR4A1NR4A2NR4A3 | |
| SCHEMBL3595587 | 0.84 | TBXAS1 (0.46) | TBXAS1PTPN1NR4A1NR4A2NR4A3 | |
| SCHEMBL3586928 | 0.82 | TBXAS1 (0.43) | TBXAS1PTPN1NR4A1NR4A2NR4A3 | |
| SCHEMBL27750917 | 0.81 | TBXAS1 (0.43) | TBXAS1PTPN1NR4A1NR4A2NR4A3 | |
| SCHEMBL273714 | 0.79 | TBXAS1 (0.45) | TBXAS1PTPN1NR4A1NR4A2NR4A3 | |
| SCHEMBL273239 | 0.78 | KDR (0.61) | ALDH1A1LMNAL3MBTL1 | |
| SCHEMBL273411 | 0.75 | KDR (0.57) | LMNAKDM4ERAB9AL3MBTL1 | |
| SCHEMBL2709291 | 0.75 | TBXAS1 (0.60) | TBXAS1PTPN1NR4A1NR4A2NR4A3 | |
| SCHEMBL9761825 | 0.73 | PTPN1 (0.62) | TBXAS1PTPN1NR4A1NR4A2NR4A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120122857-A1 | HETEROBICYCLIC CARBOXAMIDES AS INHIBITORS FOR KINASES | NOVARTIS AG (CH) | 2012-05-17 | — | — | US | claimed |
| US-20100029626-A1 | Cyclic sulfones useful as mitochondrial sodium-calcium exchangers | NOVARTIS AG (CH) | 2010-02-04 | — | — | US | claimed |
| CN-101443318-A | Heterobicyclic carboxamides as inhibitors for kinases | NOVARTIS AG (CH) | 2009-05-27 | — | — | CN | claimed |
| EP-1996558-A1 | HETEROBICYCLIC CARBOXAMIDES AS INHIBITORS FOR KINASES | Novartis AG (CH) | 2008-12-03 | — | — | EP | claimed |
| WO-2007104538-A1 | HETEROBICYCLIC CARBOXAMIDES AS INHIBITORS FOR KINASES | NOVARTIS AG (CH) | 2007-09-20 | — | — | WO | claimed |
| US-20120122857-A1 | HETEROBICYCLIC CARBOXAMIDES AS INHIBITORS FOR KINASES | NOVARTIS AG (CH) | 2012-05-17 | — | — | US | disclosed |
| US-8133886-B2 | Heterobicyclic carboxamides as inhibitors for kinases | NOVARTIS AG (CH) | 2012-03-13 | — | — | US | disclosed |
| EP-2371822-A1 | Heterobicyclic carboxamides as inhibitors for kinases | Novartis AG (CH) | 2011-10-05 | — | — | EP | disclosed |
| US-20100029626-A1 | Cyclic sulfones useful as mitochondrial sodium-calcium exchangers | NOVARTIS AG (CH) | 2010-02-04 | — | — | US | disclosed |
| CN-101443318-A | Heterobicyclic carboxamides as inhibitors for kinases | NOVARTIS AG (CH) | 2009-05-27 | — | — | CN | disclosed |
| EP-1996558-A1 | HETEROBICYCLIC CARBOXAMIDES AS INHIBITORS FOR KINASES | Novartis AG (CH) | 2008-12-03 | — | — | EP | disclosed |
| WO-2007104538-A1 | HETEROBICYCLIC CARBOXAMIDES AS INHIBITORS FOR KINASES | NOVARTIS AG (CH) | 2007-09-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029626-A1 | Cyclic sulfones useful as mitochondrial sodium-calcium exchangers | SLC8B1, MCU, GLS | TBXAS1 905/4885PTPN1 1914/4885NR4A1 4621/4885 |
| US-20120122857-A1 | HETEROBICYCLIC CARBOXAMIDES AS INHIBITORS FOR KINASES | MAP3K20, PHKG1, PHKG2 | TBXAS1 872/4885PTPN1 1611/4885NR4A1 3735/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.